MedTrace Logo

Optimizing the Ocular Surface Prior to Cataract Surgery

NCT02766907 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-03-19

Study results available
· View outcomes & findings →

Summary

Prospective study to evaluate the efficacy of using self-retained cryopreserved amniotic membrane after debridement in treating Epithelial Base Membrane Dystrophy (EBMD) to optimize the ocular surface integrity and intraocular lens calculation before cataract surgery.

Conditions

  • Corneal Dystrophy, Epithelial Basement Membrane

Interventions

DEVICE

cryopreserved amniotic membrane

placement of cryopreserved amniotic membrane after routine debridement procedure for EBMD

Sponsors & Collaborators

  • BioTissue Holdings, Inc

    lead INDUSTRY

Principal Investigators

  • Elizabeth Yeu, MD · Virginia Eye Consultants

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2017-01-31
Completion
2018-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02766907 on ClinicalTrials.gov